Search

for
Search:

GlossaryBortezomib

inhibits proteasomes to treat multiple myeloma and lymphoma

Bortezomib, also known by the brand name Velcade, is a medication used primarily to treat multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasomes, which are enzyme complexes that break down proteins in cells, thereby causing cancer cells to die. This targeted action helps to control the growth and spread of cancerous cells.

Related Terms

Sort by

Community Join

30 / 1000+ results

community Ruxolitinib - Start of a case study

in Research/Science 10 upvotes 2 years ago

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

community Kintor Phase 2 Results released KX-826 (pyrilutamide)

in Research/Science 444 upvotes 3 years ago

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

community Has anyone seen this study before? It claims that B6+Zinc can inhibit 5ar activity

in Technology 77 upvotes 3 years ago

The conversation discusses using B6 and Zinc to inhibit 5ar activity, similar to Fin and Dut. Minoxidil is mentioned as a supplementary treatment.

community Group Buy for MR antagonist finerenone

in Product 11 upvotes 3 years ago

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

community Anagenic is trying to compound Gt20029

in Treatment 56 upvotes 3 years ago

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

community GT20029. Kintor Pharma’s Product

in Research/Science 12 upvotes 3 years ago

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

community Bicalutamide and muscles growth

in Female 8 upvotes 1 year ago

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

community Fevipiprant 2019!

15 upvotes 9 years ago

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited

in Research/Science 58 upvotes 3 years ago

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

community Huge Group Buy is Now Live with New and Existing Treatments

in Product 146 upvotes 2 years ago

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

community Brief update clascoterone phase 3 - Breezula

in Research/Science 4 upvotes 2 years ago

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

community Best Treatment In The Pipeline?

in Chat 15 upvotes 1 year ago

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety

in Technology 54 upvotes 2 years ago

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

community Future hope ? What do you guys predict ? clascoterone, pyrilutamide, gt20029 etc.

in Treatment 15 upvotes 4 years ago

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

community Pyrilutamide cease and desist from Kintor

in Transplants 12 upvotes 3 years ago

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?

in Chat 17 upvotes 4 years ago

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

community OFFICIAL Multi-Center Verteporfin Trial Recruitment

in Research/Science 251 upvotes 1 year ago

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

community Link to the conference for Kintor Pyrilutamide

in Research/Science 39 upvotes 4 years ago

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

community pyrilutamide solution progress log

in Product 20 upvotes 3 years ago

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

community Pyrilutamide Phase 3 on its way

in Treatment 128 upvotes 4 years ago

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

community Ru-58841 vs KX-826/pyrilutamide while on steroids

in Finasteride/Dutasteride 5 upvotes 1 year ago

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

community Has anyone else seen this encouraging verteporfin case study?

in Progress Pictures 35 upvotes 2 years ago

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

community Kintor long term safety phase 3

in Research/Science 66 upvotes 1 year ago

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

community BPC-157 and Angiogenesis. Bro-Science-Execution-Plan

in Research/Science 13 upvotes 11 months ago

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

community First patient dosed with Pyrilutamide (Kintor) Phase III

in Research/Science 199 upvotes 4 years ago

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

community Cassiopea announces completion of recruitment of Phase II dose ranging trial of Breezula (CB-03-01) for androgenic alopecia

10 upvotes 8 years ago

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

community Will kintor show pyrilutamide phase 3 trials result this q

in Treatment 2 upvotes 2 years ago

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound

in Research/Science 128 upvotes 3 years ago

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

community Kintors 1% Pyrilutamide comes in October/November

in Treatment 21 upvotes 1 year ago

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

community Kintor is starting a new phase III KX-826 combined with Minoxidil

in Treatment 24 upvotes 2 years ago

Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.